2026年11月4日星期三
M
Meridian Globe
ព័ត៌មានបន្ទាន់
NTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

ប្រភព Nature 生命科学1 ថ្ងៃមុន
Summary

យើងផ្តល់តែសន្ទស្សន៍ចំណងជើង និងសេចក្តីសង្ខេប។ ខ្លឹមសារពេញលេញ និងសិទ្ធិអ្នកនិពន្ធ ជាកម្មសិទ្ធិរបស់ប្រភពដើម — សូមចុចតំណដើមដើម្បីអាន។

បើកឯកសារដើម
ផ្នែកព័ត៌មាន
Science
តំបន់
Global
Language
English
Item ID
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Meridian Globe